Non-Small Cell Lung Cancer New Drug: Selpercatinib in RET-Fusion Positive NSCLC Ulas D. Bayraktar, MD 2022-11-26
Diffuse Large B Cell Lymphoma New Indication: Polatuzumab in Untreated DLBCL Ulas D. Bayraktar, MD 2022-11-26
Breast Cancer New Reference: Pembrolizumab in Triple-Negative Breast Cancer Ulas D. Bayraktar, MD 2022-11-26
Gastrointestinal Stromal Tumor New Drug: Ripretinib for Advanced GIST Ulas D. Bayraktar, MD 2022-09-20
Non-Small Cell Lung Cancer New Indication: Neoadjuvant Nivolumab for NSCLC Ulas D. Bayraktar, MD 2022-09-20
Mantle cell lymphoma New Protocol: Ibrutinib with Rituximab and Bendamustine for Mantle Cell Lymphoma Ulas D. Bayraktar, MD 2022-09-20
Follicular Lymphoma New Protocol: Lenalidomide-Rituximab for Untreated Follicular Lymphoma Ulas D. Bayraktar, MD 2022-09-20
Renal Cell Carcinoma New Reference: Nivolumab and Cabozantinib for Advanced RCC Ulas D. Bayraktar, MD 2022-09-20
